5333-76-6Relevant academic research and scientific papers
Synthesis of pyrrolidin-2-ones via tandem reactions of vinyl sulfonium salts under mild conditions
Xie, Chunsong,Han, Deyu,Hu, Yue,Liu, Jinhua,Xie, Tian
, p. 5238 - 5241 (2010)
A novel and efficient synthesis of pyrrolidin-2-ones through the tandem reactions of vinyl sulfonium salts with malonyl amides under very mild conditions is reported. The reaction demonstrates a wide tolerance toward various aryls, acyl, sulfonyl, and benzyl while aliphatic groups delivering the tetrahydro-2-oxofuran product.
DRUG COMPOSITION HAVING ACTIVE INGREDIENT ADHERED AT HIGH CONCENTRATION TO SPHERICAL CORE
-
Page/Page column 46, (2010/02/14)
Granule, fine particle or tablet of excellent leaching property, comprising a drug active ingredient in high content realized by forming a layer containing drug active ingredient on core particles through a combination of a method of dispersing and adhering an active ingredient while spraying or adding a binder with a method of spraying or adding a solution or suspension wherein an active ingredient and a binder are contained so as to effect adhesion. Further, there are provided a drug composition containing such a granule, fine particle or tablet and a process for producing the same.
CONTROLLED RELEASE COMPOSITION
-
Page/Page column 51, (2010/02/15)
The present invention provides a controlled release composition showing release of an active ingredient (proton pump inhibitor) controlled in two or more steps at different release rates, which contains1) a release-controlled part A capable of controlling release of the active ingredient to occur at a predetermined rate,2) a release-controlled part B capable of controlling release of the active ingredient to occur at a predetermined rate lower than the release rate of the release-controlled part A, and where necessary, 3) a release-controlled part C capable of controlling release of the active ingredient to occur at a predetermined rate faster than the release rate of the release-controlled part B, wherein the release of the active ingredient from the release-controlled part B precedes the release of the active ingredient from the release-controlled part A (when release-controlled part C is contained, the release of the active ingredient from the release-controlled part C precedes the release of the active ingredient from the release-controlled part B).
